



Second vaccination unnecessary for COVID-19 recovered patients

August 2021

A new Vienna study with MedUni Wien Biobank involvement shows:

A second dose of the Biontech and Pfizer vaccine against Covid-19 is not necessary for those who have recovered from COVID-19 disease. The results were published by Viennese laboratory physicians in the "European Journal of Clinical Investigation".

More than 660,000 people in Austria and more than 200 million worldwide have already been infected with SARS-CoV-2. This raised the question of how to proceed with vaccination of Covid-19 recovered patients.

Perkmann and co-authors have demonstrated in their study on 69 people without a previous infection (seronegative) and 12 people who had recovered from Covid-19: All received a dose of the Covid-19 vaccine from Pfizer and Biontech. After 21 days they were examined for the concentration of antibodies in the blood. It turned out that the antibody concentration after the primary vaccination of convalescents differed more than a hundred times or more than 20 times that of those vaccinated for the first time without a previous Covid-19 episode, depending on the test method.

All 69 subjects without SARS-CoV-2 infection and with a primary vaccination and all 12 recovered study participants with a vaccination finally received the second dose of the mRNA vaccine. As a result, the antibody concentration in participants without SARS-CoV-2 disease increased by 25 times compared to the value after the initial vaccination. In those participants who had recovered from SARS-CoV-2 illness, the antibody concentration only increased by about half compared to the concentration after the first dose.

According to these study results, you can save yourself the double vaccination of SARS-CoV-2 convalescents. However, it would be important that international vaccination certificates, "green passports", etc., clearly identify the existing vaccination protection for such persons, even with a partial vaccination.

Read original ORF media report (wien.ORF.at Agenturen; 10 Aug 2021): https://wien.orf.at/stories/3116303/

Read original Kurier report: https://kurier.at/wissen/gesundheit/corona-zweitimpfung-beigenesenen-nicht-notwendig/401468071

Read original publication (open access):

Perkmann T., ..., Mucher P., ..., Haslacher H. Serum antibody response to BNT162b2 after natural SARS- CoV-2 infection. Eur J Clin Invest 2021 Aug 1;e13632. doi: 10.1111/eci.13632. Online ahead of print https://onlinelibrary.wiley.com/doi/10.1111/eci.13632

 $\frac{https://www.sciencedirect.com/science/article/pii/S1201971221006202?via\%3Dihubhttps://journals.asm.org/doi/10.1128/Spectrum.00247-21$



VILEY

Serum antibody response to BNT162b2 after natural SARS-CoV-2 infection

Thomas Perkmann

| Nicole Perkmann-Nagele¹ | Thomas Koller¹ | Patrick Mucher¹
| Astrid Radakovics¹ | Michael Wolzt² | Oswald F. Wagner¹ | Christoph J. Binder¹ |

Department of Laboratory Medicine, Medical University of Victora, Victora, Asseria Department of Clinical Pharmacology, Medical University of Victora, Victora,

Abstract
Background: There is preliminary evidence that individuals with previous SAF
CoV-2 infections exhibit a more pronounced artifledy response. However, these
samppines have not yet been supported by data obtained through various CE-mark
tests. This study aimed to close this gap.

to the Department of the Depart

Results: After a single done of BYTCH25, individuals after recursal SMS-EXV.

Individual persons the transition of the transition of the single reference in the single reference of the single refere

neuro rac o surpositivo.

Condisionis: Corproper with rative individuals, seropositives after natural SA

CoV-2 infection presented with a substantially higher antibody response already
dose in GNT1600, as measured by two Chranticel in vitro diagnosis tests as
SVNT. These results should simulate discussion and neuration on whether indiv
als after previous SARS-CoV-2 infection would benefit from a two-put vaccial.

Image: Eur J Clin Invest

KURIER ® ABONNIEREN .



WISSEN GESUNDHEIT

10.08.2021

Zweitimpfung bei Genesenen nicht notwendig

Personen, die eine Covid-Erkrankung überstanden haben, entwickeln nach der ersten mRNA-Impfdosis hohe Antikörperspiegel.

Image: Kurier



BBMRLat | Neue Stiftingtalstasse 2/B/6, 8010 Graz - AUSTRIA

Bundesministerium
Bildung, Wissenschaft
und Forschung

Funded by

GZ 10.470/0016-II/3/2013 (2013-2018)

BMBWF-10.470/0010-V/3q/2018 (2018-2023)

Login